Structure-based design of prefusion-stabilized SARS-CoV-2 spikes

The coronavirus disease 2019 (COVID-19) pandemic has led to accelerated efforts to develop therapeutics and vaccines. A key target of these efforts is the spike (S) protein, which is metastable and difficult to produce recombinantly. We characterized 100 structure-guided spike designs and identified...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Science (American Association for the Advancement of Science) 2020-09, Vol.369 (6510), p.1501-1505
Hauptverfasser: Hsieh, Ching-Lin, Goldsmith, Jory A, Schaub, Jeffrey M, DiVenere, Andrea M, Kuo, Hung-Che, Javanmardi, Kamyab, Le, Kevin C, Wrapp, Daniel, Lee, Alison G, Liu, Yutong, Chou, Chia-Wei, Byrne, Patrick O, Hjorth, Christy K, Johnson, Nicole V, Ludes-Meyers, John, Nguyen, Annalee W, Park, Juyeon, Wang, Nianshuang, Amengor, Dzifa, Lavinder, Jason J, Ippolito, Gregory C, Maynard, Jennifer A, Finkelstein, Ilya J, McLellan, Jason S
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The coronavirus disease 2019 (COVID-19) pandemic has led to accelerated efforts to develop therapeutics and vaccines. A key target of these efforts is the spike (S) protein, which is metastable and difficult to produce recombinantly. We characterized 100 structure-guided spike designs and identified 26 individual substitutions that increased protein yields and stability. Testing combinations of beneficial substitutions resulted in the identification of HexaPro, a variant with six beneficial proline substitutions exhibiting higher expression than its parental construct (by a factor of 10) as well as the ability to withstand heat stress, storage at room temperature, and three freeze-thaw cycles. A cryo-electron microscopy structure of HexaPro at a resolution of 3.2 angstroms confirmed that it retains the prefusion spike conformation. High-yield production of a stabilized prefusion spike protein will accelerate the development of vaccines and serological diagnostics for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
ISSN:0036-8075
1095-9203
DOI:10.1126/science.abd0826